Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
48.5 EUR | -0.51% |
|
-0.72% | -6.47% |
Jul. 02 | DRAEGERWERK : Jefferies maintains a Sell rating | ZD |
Jun. 20 | Warburg Research raises target for Drägerwerk to 64 euros - 'Buy' | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- With a P/E ratio at 10.3 for the current year and 8.73 for next year, earnings multiples are highly attractive compared with competitors.
- The company shows low valuation levels, with an enterprise value at 0.29 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.47% | 927M | B+ | ||
+0.59% | 204B | B | ||
+3.92% | 178B | B- | ||
+30.07% | 156B | B- | ||
+32.42% | 113B | A- | ||
+2.02% | 64.26B | A- | ||
+19.65% | 54.98B | B+ | ||
-1.86% | 47.44B | B+ | ||
-9.53% | 36.7B | A | ||
-1.28% | 34.84B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRW3 Stock
- Ratings Drägerwerk AG & Co. KGaA